Addyi Seasonal Use Considerations: What Clinicians and Patients Need to Know

What Is Flibanserin and Why Does Seasonality Matter?

Flibanserin is a non-hormonal, centrally acting agent that works as a 5-HT1A agonist and 5-HT2A antagonist, with secondary dopamine D4 activity. The FDA approved it in August 2015 for generalized acquired HSDD in premenopausal women who have not been diagnosed with a comorbid psychiatric disorder that better explains low desire. The drug's label carries a boxed warning for severe hypotension and syncope when co-ingested with alcohol.

Seasonality matters for three clinical reasons. First, social alcohol consumption rises sharply in late-November through early-January and again around summer holidays, raising co-ingestion risk. Second, summer heat independently worsens orthostatic hypotension, compounding the drug's cardiovascular side-effect profile. Third, winter seasonal affective patterns alter both baseline desire and CNS-depressant side-effect tolerance, complicating the HSDD diagnosis itself.

None of the key trials were powered to detect seasonal sub-group differences. That absence of data does not mean season is irrelevant. It means clinicians must extrapolate from flibanserin's pharmacology and from the broader literature on seasonality in sexual function and CNS drug tolerability.

The BEGONIA Trial: Efficacy Baseline

The BEGONIA trial (N=1,378, published in the Journal of Sexual Medicine in 2014) remains the most-cited phase 3 dataset for flibanserin in premenopausal women. Derogatis et al. (2014) reported that women randomized to flibanserin 100 mg at bedtime experienced a statistically significant increase in the number of satisfying sexual events (SSEs) compared with placebo over 24 weeks, alongside improvements in the Female Sexual Function Index desire domain and reductions in distress scores on the Female Sexual Distress Scale-Revised.

The placebo response rate was substantial, around 30 to 40% of participants showing improvement, a finding consistent with the high psychological and relational component of HSDD. Clinicians initiating therapy in winter months should be aware that seasonal mood improvement in spring can itself inflate the apparent drug response, and seasonal mood worsening in autumn can attenuate it.

FDA Label Efficacy Data in Context

Across the three key trials submitted for FDA approval, flibanserin produced a mean increase of approximately 0.5 to 1.0 additional SSEs per month versus placebo, as summarized in the FDA medical review. Critics have noted this effect size is modest. The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction notes that patient-reported distress reduction, not just event frequency, should anchor the treatment decision. Clinicians should use both metrics when evaluating whether a patient's response warrants continuing through a low-desire season.

Alcohol Interaction: The Highest-Stakes Seasonal Risk

The alcohol-flibanserin interaction is the most clinically pressing seasonal consideration. This is not a theoretical pharmacokinetic footnote. A dedicated alcohol interaction study using a 0.4 g/kg ethanol dose (roughly two standard drinks) showed that combining alcohol with flibanserin 100 mg produced episodes of severe hypotension and syncope in six of 23 subjects (26%), compared with none in the alcohol-alone arm. The FDA safety review classified this interaction as a contraindication, not a warning.

Why the Holiday Season Amplifies This Risk

Per-capita alcohol consumption in the United States peaks in December, with a secondary peak around July 4th weekend and Labor Day. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) reports that holiday-period drinking accounts for a disproportionate share of annual alcohol-related emergency visits.

For a patient taking flibanserin nightly, a single glass of wine at a holiday dinner before bedtime is a contraindicated exposure. The mechanism involves additive CNS depression plus flibanserin-mediated inhibition of CYP3A4 by high ethanol concentrations, raising flibanserin area-under-the-curve by roughly 170% in some pharmacokinetic modeling scenarios cited in the label.

Counseling Points Timed to the Calendar

Clinicians should proactively re-address alcohol abstinence at the October or November prescription refill visit, before the holiday window opens. A simple script: "Flibanserin is contraindicated with any alcohol. That includes wine at dinner, a single cocktail, and champagne at midnight. If you plan to drink at an event, skip that night's dose and resume the next night." This skip-and-resume approach is not formally validated in a trial, but it aligns with the drug's approximately 11-hour half-life and the FDA's advice that patients who cannot commit to full abstinence should not be prescribed flibanserin.

The Addyi REMS program requires patient enrollment and signed acknowledgment of the alcohol restriction before each fill. Reinforce this at seasonal counseling check-ins rather than treating the REMS signature as a one-time administrative step.

Summer Heat, Hypotension, and Syncope Risk

Flibanserin's label lists dizziness, somnolence, nausea, and hypotension as the most common adverse effects leading to discontinuation. These effects are dose-dependent and most prominent in the first two weeks of therapy. Summer heat adds an independent orthostatic hypotension vector through cutaneous vasodilation and dehydration.

Pharmacology of the Heat-Hypotension Overlap

Peripheral vasodilation from environmental heat reduces venous return. Flibanserin's dopaminergic and serotonergic activity independently lowers peripheral vascular resistance. The combination may not be additive in a simple linear sense, but both mechanisms converge on reduced cerebral perfusion pressure when the patient stands from bed at night to use the bathroom, which is the highest-risk moment given bedtime dosing.

No published study has specifically examined flibanserin hemodynamic effects stratified by ambient temperature. Clinicians must extrapolate from general pharmacology. The ACC/AHA hypertension guideline (2017) identifies heat exposure and dehydration as modifiable orthostatic hypotension precipitants in patients on vasodilatory CNS drugs.

Practical Summer Management

Patients should be counseled to:

• Maintain adequate hydration throughout the day, targeting at least 2 liters of water in high-heat conditions.
• Rise slowly from bed if they wake during the night.
• Avoid taking flibanserin within two hours of a hot bath or sauna.
• Report any new episodes of lightheadedness to their prescriber within 48 hours.

Patients with a baseline orthostatic drop exceeding 20 mmHg systolic, or those on concomitant antihypertensives, deserve closer monitoring from June through August. A blood pressure check at the summer refill visit takes under two minutes and catches decompensated orthostasis before it becomes a fall or syncope event.

Winter, Seasonal Mood, and the HSDD Differential

HSDD and seasonal affective disorder (SAD) share overlapping symptom domains: low energy, reduced pleasure in previously enjoyable activities, and social withdrawal. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) specifies that HSDD should not be diagnosed when low desire is better explained by a mood disorder. This creates a clinical problem every autumn and winter.

Distinguishing HSDD from SAD-Related Low Desire

A patient who loses sexual desire in October and regains it in March may have SAD-driven low desire, not generalized acquired HSDD. Flibanserin is not indicated for this pattern, and initiating it in October risks attributing spring desire recovery to the drug rather than to seasonal mood normalization.

The DSM-5 criteria for HSDD require that symptoms persist for a minimum of six months and cause clinically significant distress. A structured six-month symptom history spanning at least one seasonal cycle is appropriate before prescribing. If a patient's history shows a clear winter nadir and summer peak in desire, addressing the SAD component first (light therapy, CBT, or pharmacotherapy with a non-serotonergic agent where possible) is the right sequence.

CNS Side-Effect Burden in Winter

Flibanserin's most common adverse effects are somnolence (reported in approximately 11% of flibanserin-treated patients in key trials versus 4% placebo) and fatigue. In winter, baseline melatonin secretion increases, circadian phase is delayed, and many patients already report higher daytime fatigue. Initiating flibanserin in December or January may feel intolerable to a patient whose CNS is already suppressed by photoperiod changes, even if the same dose was well-tolerated in summer.

One practical approach: if a patient is newly initiating flibanserin, consider a spring or early-summer start when daytime alertness is highest and somnolence side effects are most distinguishable from background fatigue. This is not a label-based requirement. It is a clinical judgment based on the drug's side-effect profile and seasonal biology.

Drug Interactions With Seasonal OTC Products

Autumn and Winter Cold Season

CYP3A4 inhibitors raise flibanserin plasma concentrations and are contraindicated or require dose adjustment. Moderate CYP3A4 inhibitors (fluconazole, certain antiretrovirals) are addressed in the label. Less discussed: several OTC products patients reach for in cold and flu season carry CYP3A4 inhibitory potential.

Grapefruit juice, a staple of breakfast routines that patients often increase in winter for vitamin C, inhibits intestinal CYP3A4. Data summarized by the FDA confirm that grapefruit-CYP3A4 interactions can raise drug AUC by 20 to 200% depending on the substrate. Patients on flibanserin should avoid grapefruit and grapefruit juice.

Cimetidine, available OTC for heartburn and commonly used around heavy holiday meals, is a non-specific CYP inhibitor. While its CYP3A4 inhibitory potency is modest, it also inhibits CYP2C19, flibanserin's secondary metabolic pathway, potentially raising systemic exposure further.

Spring and Summer Allergy Season

St. John's Wort, often self-initiated in spring for mood support, is a potent CYP3A4 inducer. A NIH-hosted review of herb-drug interactions documents St. John's Wort reducing plasma concentrations of CYP3A4 substrates by 30 to 70%. Patients taking it alongside flibanserin may experience loss of efficacy.

First-generation antihistamines (diphenhydramine, hydroxyzine) used for spring allergies or as sleep aids compound flibanserin's CNS depressant effects. Second-generation antihistamines (loratadine, cetirizine) are preferred for patients on flibanserin.

Adherence Patterns and the 8-Week Response Window

The FDA label specifies that patients who do not show improvement after 8 weeks of daily bedtime dosing should discontinue flibanserin. Adherence is thus clinically critical: a patient who misses two weeks of doses in December due to holiday travel and alcohol avoidance difficulty has effectively lost a quarter of her response assessment window.

Strategies for Maintaining Adherence Through High-Risk Periods

Bedtime dosing is anchored to sleep, which is advantageous for habit formation. Most adults have a consistent bedtime routine. Linking flibanserin to another nightly habit (brushing teeth, skincare routine) reduces the cognitive load of remembering a dose.

For the holiday season specifically, clinicians can offer patients explicit written guidance: "If you know you will be drinking alcohol on a specific evening, skip that night's dose. Do not double-dose the following night. Simply resume your usual bedtime dose." This practical instruction reduces the likelihood of a patient abandoning the medication entirely after one social event.

A 2021 analysis of medication persistence data for CNS-active drugs published in JAMA Network Open found that patient-reported counseling quality at initiation was among the strongest predictors of 90-day adherence. The seasonal context counseling described here is an extension of initiation-quality counseling, not an optional add-on.

Patient Selection and Timing of Initiation

Who Should Not Start Flibanserin in Winter

Patients with the following profiles should have their flibanserin initiation deferred or carefully staged in winter months:

• Active or subthreshold SAD with desire symptoms present only in winter (consider treating the mood disorder first).
• Heavy planned alcohol use during the holiday season (counsel on abstinence requirement and defer if adherence is unlikely).
• Concurrent use of CYP3A4 inhibitors initiated for seasonal illnesses (azithromycin is a weak inhibitor, but clarithromycin or fluconazole for seasonal sinusitis are moderate inhibitors and are contraindicated on label).
• Baseline orthostatic hypotension already worsened by seasonal dehydration.

Who Benefits From a Spring or Early-Summer Start

Patients who are in stable mood, abstinent from alcohol, not on interacting medications, and have confirmed six-month-persistent HSDD symptoms may actually tolerate initiation better in April through June. Longer days improve circadian alertness, reducing the perceived burden of somnolence. Social alcohol consumption is more predictable and manageable outside major holiday windows. The 8-week response assessment then concludes by late July or August, a natural time for a scheduled telehealth follow-up.

Monitoring Schedule Aligned to the Calendar

A structured seasonal monitoring calendar for patients on flibanserin:

October-November visit: Re-consent on alcohol abstinence before holiday season. Review any new medications added for fall illnesses. Assess for SAD symptom emergence. Confirm REMS re-enrollment if required at pharmacy.

January visit: Assess 8-week response if initiated in November. Evaluate somnolence and fatigue burden through winter. Document SSE frequency using a validated tool (Female Sexual Function Index or Patient-Reported Outcomes Measurement Information System Sexual Function domain).

April-May visit: Re-evaluate desire trajectory as seasonal mood normalizes. If desire has substantially improved without dose change, consider whether SAD-component was contributing. Counsel on grapefruit and OTC herb interactions as spring supplements increase.

July-August visit: Summer heat counseling. Orthostatic blood pressure check. Review hydration habits. Confirm no new vasodilatory medications added.

The Endocrine Society 2019 guideline on female sexual dysfunction recommends reassessment at 3-month intervals for pharmacologically treated HSDD, which aligns well with a seasonally structured four-visit annual framework.